OpenLB
Open Library of Bioscience
Advanced Search
Drug design, development and therapy
2021;15 2815-2830.

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.

Stephani L Stancil, Fuad Mirzayev, Susan M Abdel-Rahman
Author Information
  1. Stephani L Stancil: Division of Adolescent Medicine, Children's Mercy Kansas City, Kansas City, MO, 64108, USA.
  2. Fuad Mirzayev: World Health Organization, Geneva, Switzerland.
  3. Susan M Abdel-Rahman: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, MO, 64108, USA.
PMID: 34234413 DOI: 10.2147/DDDT.S281639

Abstract

Tuberculosis (TB) is the most deadly infectious disease globally. Although most individuals achieve a cure, a substantial portion develop multi-drug resistant TB which is exceedingly difficult to treat, and the number of effective agents is dwindling. Development of new anti-tubercular medications is imperative to combat existing drug resistance and accelerate global eradication of TB. Pretomanid (PA-824) represents one of the newest drug classes (ie, nitroimidazooxazines) approved in 2019 by the United States Food and Drug Administration as part of a multi-drug regimen (with bedaquiline and linezolid, BPaL) and recommended by the World Health Organization (WHO) to treat extensively-resistant (XR-TB) and multi-drug resistant tuberculosis (MDR-TB). Approval was granted through the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs, which accelerates approval for antimicrobial drugs used to treat life-threatening or serious infections in a limited population with unmet need. This review details the pharmacology, efficacy, and safety of this new agent and describes evidence to date for its role in the treatment of drug resistant TB including published, ongoing, and planned studies.

Keywords

antimicrobial multi-drug resistant pretomanid tuberculosis

References

  1. Int J Tuberc Lung Dis. 2021 Apr 1;25(4):305-314 [PMID: 33762075]
  2. Antimicrob Agents Chemother. 2009 Sep;53(9):3720-5 [PMID: 19528280]
  3. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3202-6 [PMID: 26953211]
  4. Antimicrob Agents Chemother. 2015 Jan;59(1):136-44 [PMID: 25331696]
  5. Br J Clin Pharmacol. 2021 Jan;87(1):140-151 [PMID: 32415743]
  6. Antimicrob Agents Chemother. 2020 Dec 16;65(1): [PMID: 33077660]
  7. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12828-33 [PMID: 8917504]
  8. Molecules. 2020 May 22;25(10): [PMID: 32456032]
  9. PLoS Pathog. 2012 Sep;8(9):e1002946 [PMID: 23028335]
  10. J Antimicrob Chemother. 2018 Sep 1;73(9):2305-2313 [PMID: 29701775]
  11. Mol Microbiol. 2003 Apr;48(1):77-84 [PMID: 12657046]
  12. Tuberculosis (Edinb). 2018 Jan;108:186-194 [PMID: 29523322]
  13. Lancet. 2012 Sep 15;380(9846):986-93 [PMID: 22828481]
  14. Nat Commun. 2019 Apr 5;10(1):1558 [PMID: 30952857]
  15. CPT Pharmacometrics Syst Pharmacol. 2021 Mar;10(3):211-219 [PMID: 33440076]
  16. Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52 [PMID: 24957823]
  17. ACS Med Chem Lett. 2017 Nov 13;8(12):1275-1280 [PMID: 29259747]
  18. Antimicrob Agents Chemother. 2015;59(6):3518-28 [PMID: 25845869]
  19. Antimicrob Agents Chemother. 2011 Jan;55(1):239-45 [PMID: 20937781]
  20. Eur Respir J. 2021 Jun 4;57(6): [PMID: 33243847]
  21. Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31 [PMID: 22430968]
  22. Clin Pharmacokinet. 2019 Jun;58(6):747-766 [PMID: 30406475]
  23. Antimicrob Agents Chemother. 2014;58(4):2316-21 [PMID: 24492372]
  24. Antimicrob Agents Chemother. 2005 Jun;49(6):2294-301 [PMID: 15917524]
  25. Antimicrob Agents Chemother. 2005 Jun;49(6):2289-93 [PMID: 15917523]
  26. Antimicrob Agents Chemother. 2017 Aug 24;61(9): [PMID: 28630203]
  27. Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12989-94 [PMID: 14569030]
  28. Int J Antimicrob Agents. 2014 Dec;44(6):564-6 [PMID: 25270632]
  29. J Pharm Biomed Anal. 2014 Aug;97:1-8 [PMID: 24798753]
  30. Obstet Gynecol. 2020 Jun;135(6):1444-1453 [PMID: 32459437]
  31. N Engl J Med. 2020 Mar 5;382(10):893-902 [PMID: 32130813]
  32. Antimicrob Agents Chemother. 2021 Jan 20;65(2): [PMID: 33229425]
  33. Sci Rep. 2018 Mar 23;8(1):5084 [PMID: 29572459]
  34. J Infect Dis. 2012 Feb 15;205(4):595-602 [PMID: 22198962]
  35. Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53 [PMID: 25622149]
  36. Antimicrob Agents Chemother. 2013 Nov;57(11):5516-20 [PMID: 23979737]
  37. Environ Health Perspect. 1985 Dec;64:199-208 [PMID: 3830698]
  38. PLoS Pathog. 2020 Feb 7;16(2):e1008287 [PMID: 32032366]
  39. Tuberculosis (Edinb). 2012 Nov;92(6):453-88 [PMID: 22940006]
  40. Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8327-32 [PMID: 15928073]
  41. Lancet. 2015 May 2;385(9979):1738-1747 [PMID: 25795076]
  42. J Bacteriol. 2002 May;184(9):2420-8 [PMID: 11948155]
  43. J Chromatogr Sci. 2018 Apr 1;56(4):327-335 [PMID: 29373758]
  44. BMJ Open. 2020 Oct 10;10(10):e036599 [PMID: 33039989]
  45. Antimicrob Agents Chemother. 2020 Dec 16;65(1): [PMID: 33077652]
  46. Science. 2008 Nov 28;322(5906):1392-5 [PMID: 19039139]
  47. Xenobiotica. 2016;46(3):247-52 [PMID: 26207565]
  48. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):431-6 [PMID: 16387854]
  49. Antimicrob Agents Chemother. 2013 Aug;57(8):3699-703 [PMID: 23689718]
  50. Antimicrob Agents Chemother. 2015 Sep;59(9):5316-23 [PMID: 26100695]
  51. J Antimicrob Chemother. 2014 Feb;69(2):292-302 [PMID: 24072169]
  52. Infect Drug Resist. 2020 Mar 11;13:815-822 [PMID: 32210596]
  53. Antimicrob Agents Chemother. 2020 Oct 20;64(11): [PMID: 32900682]
  54. Eur J Med Chem. 2019 Oct 1;179:376-388 [PMID: 31260891]
  55. J Med Chem. 2020 Dec 24;63(24):15726-15751 [PMID: 33151678]
  56. Antimicrob Agents Chemother. 2019 Sep 23;63(10): [PMID: 31358590]
  57. Antimicrob Agents Chemother. 2015 Jan;59(1):129-35 [PMID: 25331697]
  58. Antimicrob Agents Chemother. 2014 May;58(5):2944-7 [PMID: 24550336]
  59. Med Res Rev. 2020 Jan;40(1):263-292 [PMID: 31254295]
  60. PLoS Med. 2006 Nov;3(11):e466 [PMID: 17132069]
  61. Antimicrob Agents Chemother. 2018 Jun 26;62(7): [PMID: 29661865]
  62. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6 [PMID: 23733473]
  63. Nature. 2000 Jun 22;405(6789):962-6 [PMID: 10879539]
  64. J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043 [PMID: 32361756]
  65. Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1293-1296 [PMID: 30953211]
  66. Antimicrob Agents Chemother. 2009 Sep;53(9):3726-33 [PMID: 19528286]
  67. J Antimicrob Chemother. 2008 Nov;62(5):1037-45 [PMID: 18693235]
  68. Mol Microbiol. 2013 Feb;87(4):744-55 [PMID: 23240649]
  69. Lancet Respir Med. 2019 Dec;7(12):1048-1058 [PMID: 31732485]
  70. J Infect Dis. 2010 Jun 1;201(11):1743-52 [PMID: 20394526]
  71. Emerg Infect Dis. 2021 Jan;27(1): [PMID: 33227229]
  72. Antimicrob Agents Chemother. 2021 Jan 20;65(2): [PMID: 33199386]
  73. PLoS One. 2013 Dec 11;8(12):e81985 [PMID: 24349169]

Grants

  1. 001/World Health Organization

MeSH Term

Animals
Antitubercular Agents
Drug Therapy, Combination
Extensively Drug-Resistant Tuberculosis
Humans
Nitroimidazoles
Tuberculosis, Multidrug-Resistant

Chemicals

Antitubercular Agents
Nitroimidazoles
pretomanid
Journal Article Review

Word Cloud

Similar Articles

Cited By